Gynecologic Cancer

Xavier Matias-Guiu Guia

PRINCIPAL INVESTIGATORS
  • Marta Gil Martin
  • Beatriz Pardo Burdalo
  • Jordi Ponce Sebastia
  • Mireia Martin Satue
  • David Llobet Navàs
  • Ruth Rodriguez Barrueco
CLINICAL RESEARCHERS
  • Maria Dolores Marti Cardona
    Maria Eulalia Fernandez Montoli
    Marc Barahona Orpinell
    Nuria Ruiz Roig
POSTDOCTORAL RESEARCHERS (R2)
  • Susana Marin Borras
  • Laura Devis Jauregui
  • Mireia Olivan Riera
PREDOCTORAL RESEARCHERS (R1)
  • Maria Esther Guerra Fernandez
  • Maria Del Rosario Taco Sanchez
  • August Vidal Bel
  • Laura Coll Iglesias
  • Aitor Rodriguez Martinez
  • Carla Trapero Candela
  • Katja Gassner
SCIENTIFIC SUPPORT
  • Rosa Maria Campos De Pablo
  • Francisco Javier Llobet Navàs
  • Axel Rodriguez Vazquez
  • Patricia García Fernández
  • Cristina Navarro López
  • Ricard Bonilla Amadeo
Cancer
Oncobell

Scientific production

46

PAPERS

10 PUBLICATIONS IN FIRST DECILE

19 PUBLICATIONS IN FIRST QUARTILE

Selected publications

  • Georgouli M, Herraiz C, Crosas-Molist E, Fanshawe B, Maiques O, Perdrix A, Pandya P, Rodriguez-Hernandez I, Ilieva KM, Cantelli G, Karagiannis P, Mele S, Lam H, Josephs DH, Matias-Guiu X, Marti RM, Nestle FO, Orgaz JL, Malanchi I, Fruhwirth GO, Karagiannis SN, Sanz-Moreno V . Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment.. CELL. 10.1016/j.cell.2018.12.038
  • Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P . Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.. LANCET ONCOLOGY. 10.1016/S1470-2045(19)30328-6
  • Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, Lesoin A, Monk BJ, Lund B, Gilbert L, Wenham RM, Benigno B, Arora S, Hazard SJ, Mirza MR . Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.. JOURNAL OF CLINICAL ONCOLOGY. 10.1200/JCO.18.02238
  • Matulonis UA, Walder L, Nøttrup TJ, Bessette P, Mahner S, Gil-Martin M, Kalbacher E, Ledermann JA, Wenham RM, Woie K, Lau S, Marmé F, Casado Herraez A, Hardy-Bessard AC, Banerjee S, Lindahl G, Benigno B, Buscema J, Travers K, Guy H, Mirza MR . Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.. JOURNAL OF CLINICAL ONCOLOGY. 10.1200/JCO.19.00917
  • Etxeberria I, Bolaños E, Quetglas JI, Gros A, Villanueva A, Palomero J, Sánchez-Paulete AR, Piulats JM, Matias-Guiu X, Olivera I, Ochoa MC, Labiano S, Garasa S, Rodriguez I, Vidal A, Mancheño U, Hervás-Stubbs S, Azpilikueta A, Otano I, Aznar MA, Sanmamed MF, Inogés S, Berraondo P, Teijeira Á, Melero I . Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells.. CANCER CELL. 10.1016/j.ccell.2019.10.006

Research highlights

PROJECTS

11 Ongoing projects
4 Started projects 

 

20 Ongoing clinical trials
5 Started clinical trials

PUBLISHED WORKS

3 Thesis

7 Clinical guidelines

Selected projects

  • Targeting the autoresistome as a new therapeutic strategy in endometrial cancer (1/12/2019 – 30/11/2022) PI: LLOBET NAVAS, DAVID. Funder: ASOCIACION ESPAÑOLA CONTRA EL CANCER.
  • Identificación de los mecanismos que conducen a la resistencia a anoikis y la diseminación metastásica en tumores ginecológicos con alto contenido en SCNA (1/1/2019 – 31/12/2021) PI: LLOBET NAVAS, DAVID. Funder: FIS-Instituto de Salud Carlos III.
  • La señalización purinérgica en la endometriosis: papel de las ecto-nucleotidasas como posibles herramientas diagnósticas y dianas terapéuticas (1/1/2019 – 31/12/2021) PI: MARTIN SATUE, MIREIA. Funder: FIS-Instituto de Salud Carlos III.
  • Descripción de nuevas dianas terapéuticas basadas en la glicosilación específica de las células madre del cáncer de mama (1/1/2019 – 31/12/2019) PI: RODRIGUEZ BARRUECO, RUTH. Funder: L’OREAL ESPAÑA.
  • Targeting the most aggressive type of endometrial carcinoma (1/11/2018 – 31/10/2023) PI: MATIAS GUIU, XAVIER. Funder: ASOCIACION ESPAÑOLA CONTRA EL CANCER.
  • Estudio de fase 1, abierto, multicéntrico y de varios grupos de MK-4830 en monoterapia y en combinación con Pembrolizumab en participantes con tumores sólidos avazados (21/11/2019 – ) PI: GIL MARTIN, MARTA. Funder ref.: MK-4830-001.
  • A randomized, open label, phase II trial of anti-PD1, TSR-042, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation (25/6/2019 – ) PI: PARDO BURDALO, BEATRIZ. Funder ref.: GEICO 78-C (ATOMICC).
  • Reveal 2: a prospective, randomized, double-blind, placebo-controlled phase 3 study of VGX-3100X delivered intramuscularly followed by electroporation with Cellectra™ 5PSP for the treatment of HPV-16 and/or HPV-18 related high grade squamous intraepithelial lesion (HSIL) of the cervix (9/4/2019 – 9/4/2025) PI: FERNANDEZ MONTOLI, MARIA EULALIA. Funder ref.: HPV-303.
  • Phase III double-blind randomized placebo controlled trial of Atezolizumab in combination with Paclitaxel and Carboplatin in women with advanced/recurrent endometrial cancer (22/2/2019 – 23/2/2023) PI: PARDO BURDALO, BEATRIZ. Funder ref.: IRFMN-EN-7556.
  • Estudio de fase 3, aleatorizado y doble ciego de quimioterapia con o sin Pembrolizumab, seguidos de mantenimiento con Olaparib o placebo, para el tratamiento de primera línea del cáncer epitelial de ovario (CEO) avanzado sin mutación de BRCA (8/2/2019 – ) PI: PARDO BURDALO, BEATRIZ. Funder ref.: MK-7339-001.